What age-based CA125 thresholds reveal about winning adoption in NHS cancer pathways NICE Redefines Ovarian Cancer Testing More women with ovarian cancer in England could be diagnosed earlier and more …
January 2026
-
-
The HAS / CNEDiMTS route explained science, law, and real-world decisions France operates one of the most structured and evidence-based reimbursement systems for medical devices in Europe. Access is not …
-
MedTech / IVD VC Funding: the investor is modelling reimbursement physics, not admiring your science Most founders pitch MedTech as if capital is attracted by novelty. In regulated healthcare, the …
-
How to Use German NUB Reimbursement Without Getting Trapped After nearly two decades of operational data, one conclusion is unavoidable: German NUB reimbursement is not a neutral innovation gateway. It …
-
Introduction: How NICE Approval in the NHS Is Now Secured Securing approval from the National Institute for Health and Care Excellence (NICE) remains one of the most decisive milestones for …
-
Why SNOMED CT and dm+d changes matter fundamentally for Digital Health, MedTech, and Biotech companies Between 2025 and 2026, the NHS will quietly implement one of the most consequential digital …